PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer

Caption

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red.

Credit

Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

Usage Restrictions

Use at least title and credit

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.